A single chain preparation of recombinant tissue-type plasminogen activator W-PA) was compared with intravenous streptokinase to determine coronary thromholytic efficacy in patients with acute myocardial infarction <3 h old. Eightysix patients were randomly selected to receive the intravenous cumulative dose of 100 mg rt-PA and 85 patients to receive 1.5 million units streptokinase. At 240 min after initiation of the thromholytic therapy noninvasive signs of sustained reperfusion occurred in 79% of patients in both groups (p = NS). Patency of the infarct-related vessel at follow-up angiography was observed in 81% of patients in the r&PA group and 74% of patients in the streptokinase group (p = NS). At hospital discharge, compared with admission, echocardiographically determined left ventricular ejection fraction increased from 52 2 11% to 56 f 10% (p <: 0.01) in the rt-PA group; changes in the streptokinase group (50 + 9% to 51 f 11%) were not significant.
A nadir value of <l g/liter fibrinogen plasma level occurred in 6 patients (7%) receiving rt-PA versus 74 patients (87%) receiving streptokinase (p < 0.0001). Plasma levels of fibrin(ogen) degradation products were more than doubled in the streptokinase group (p < 0.01). One patient in the streptokinase group developed a fatal intracranial hemorrhage; five others showed a decline in hemoglobin 25 g/dl. Other clinical events in the streptokinase-treated group included allergic reactions (four patients) and intrahospital reinfarction (two patients). None of these events occurred in the rt-PA group. This rt-PA preparation achieves a high rate of stable coronary reperfusion, comparable with that of intravenous streptokinase and is associated with fewer complications and a significant sparing of the hemostatic system.
(J Am Co11 Cardiol1989;13: [19] [20] [21] [22] [23] [24] [25] [26] that repair vascular lesions (5). Accordingly, bleeding complications are not entirely eliminated after rt-PA administration (I).
Recently, a new form of rt-PA has been developed to increase the shelf half-life and allow storage at room temperature. It consists mainly of single chain molecules and its efficacy in terms of coronary reperfusion and effects on the fibrinolytic system has recently been tested against both placebo and the old form of rt-PA consisting predominantly of two chain molecules (6-S). The focus of this study was to evaluate the coronary thrombolytic efficacy and the effects on left ventricular function of this new preparation in comparison with the standard regimen of intravenous streptokinase (9). Secondary end points of this investigation included the evaluation of safety of the drug administration as well as the effects on components of the coagulation and fibrinolytic system. MAGNANIANDTHEPAIMSINVESTIGATORS JACC Vol. 13, No. I rt-PAVERSUSSTREPTOKINASEINACUTEINFARCTION January 1989:1Y-26
Methods
Patient selection. The study was conducted in eight coordinated centers. Patients were enrolled during a 12 month period between July 1986 and June 1987. To be eligible for treatment, patients had to satisfy the following inclusion criteria: 1) age between 20 and 70 years; 2) chest pain characteristic of myocardial ischemia for 230 min, unrelieved by sublingual nitroglycerin; 3) ST segment elevation 20.1 mV in two or more standard frontal plane leads or ~0.2 mV in two or more precordial leads and ST segment depression ~0.3 mV in two or more precordial leads; and 4) time elapsed from onset of ischemic pain to recruitment 23 h.
Eligible patients were excluded for the following reasons: I) previous myocardial infarction; 2) cardiogenic shock; 3) prolonged or traumatic heart massage or tracheal intubation; 4) left bundle branch block; 5) uncontrolled hypertension (diastolic pressure ~110 mm Hg; systolic pressure 2200 mm Hg); 6) major liver or renal disease; 7) cerebrovascular accident within the last 3 months; 8) past or present bleeding disorder or significant gastrointestinal bleeding; 9) significant surgical procedure within the last 2 months; IO) previous coronary artery bypass surgery; 11) oral anticoagulant therapy; 12) childbearing age; 13) serious advanced illness; and 14) anticipated problems with cardiac catheterization or inability to cooperate.
Randomization. Eligible patients were noted in a log book and comprehensive data on all randomized patients were recorded in a basic case report form designed for computer analysis. At the time this study was planned, there was uncertainty about the reperfusion rates after thrombolytic therapy, because the Thrombolysis in Myocardial Infarction (TIMI) trial (1) had shown in the group assigned to streptokinase a reperfusion rate as low as 35%. Thus, we aimed for a total of 171 patients, 86 allocated to rt-PA and 85 to streptokinase. Allocation was performed at random and balanced at each center.
Protocol. After blood sampling for coagulation and other assays, patients randomized to the rt-PA group received the drug intravenously over 3 h at doses of 50, 20 and 20 mg at each successive hour with an initial bolus of 10 mg (total dose: 100 mg). The drug (Actilyse, supplied by Boehringer Ingelheim) was obtained by large scale suspension culture of mammalian cells transfected with cDNA encoding human t-PA and consisted predominantly of the one chain form of rt-PA. The patients allocated to streptokinase treatment received the drug intravenously over 60 min at the dose of 1.5 million units (Streptase, Istituto Behring). At 180 min after the initiation of thrombolysis a heparin infusion was begun in both groups (bolus of 40 IU/kg followed by 1,000 IUlh); the dose was adjusted to keep the level of the activated partial thromboplastin time at 1.5 to 2 times that of the control value. The anticoagulant treatment was main-tained until coronary angiography was performed. Because intravenous nitrates, concomitant with thrombolytic therapy, have been reported to increase the chances for achieving reperfusion (IO,] l), probably through an increase of the coronary flow and a consequent greater delivery of thrombolytic drug in the vicinity of the thrombus, all patients received intravenous nitroglycerin (at the maximal dose not associated with a ~10% decrease in systolic blood pressure or significant increase in heart rate) for the first 24 to 48 h.
Noninvasive assessment of reperfusion. To minimize delay in treatment, coronary angiography was not performed before thrombolysis and reperfusion was recognized by noninvasive criteria (12-15). To this end a 12 lead electrocardiogram (ECG) was recorded and the patient was asked to grade the intensity of chest pain on an analogic visual scale from 0 to 100, before starting thrombolysis. Subsequently, the I2 lead ECG and intensity of chest pain were monitored at I5 min intervals for up to 4 h and also whenever there was a change in symptoms, a change in ST segment shift on the monitor or a change in cardiac rhythm.
In addition, blood samples for determination of serum creatine kinase (CK) and MB CK activity were drawn at 2 h intervals for the initial 16 h and every 4 h for the remainder of the first 24 h after thrombolysis; thereafter enzyme levels were determined 2 times daily during the second 24 h and then 1 time daily. All the ECGs, records of chest pain behavior and enzymatic time-activity curves were analyzed in a central laboratory by two investigators who did not know the treatment assignment.
Reperfitsion NYU considered to have tclken place when the following three events occurred in a close temporal relation: 1) an abrupt abatement or a progressive reduction of chest pain; 2) a reduction of magnitude of ST segment shift that continued in sequential ECGs until it was ~50% of the basal value; and 3) a rapid increase in serum levels of MB CK with the peak occurring within 13 h (16).
The time inter& to reperfcrsion (reperfusion time) was
defined as the interval from initiation of thrombolysis to the time of onset of the resolution of the ST segment elevation. The recurrence of ST segment elevation and chest pain during thrombolysis was taken as an indication of reocclusion (17). The noninvasive assessment of reperfusion was not feasible in nine patients (four in the rt-PA group and five in the streptokinase group) because of early death or incomplete data. Enzymatic infarct size was measured according to the method of Sobel et al. (18).
Coronary angiography. Contrast left ventricular and coronary angiograms were assessed in a central laboratory by two experienced cardiologists who were unaware of patient identity and treatment allocation. Angiograms were recorded in multiple views including hemiaxial views for the left coronary artery. The infarct-related segment was identified for all films on the basis of ECG and angiographic evidence.
Qurrlith~e r~ssessrnent of' putency NYL~ perfor~nd M-
cording lo (I pretletmnined code: 0 = normal vessel with complete filling of distal vessels within three cardiac cycles: I = <50% diameter stenosis with complete filling of distal vessels within three cardiac cycles; 2 = diameter stenosis between SO and 90%) with complete filling of the distal vessel. not through collateral vessels, within three cardiac cycles: 3 = severe stenosis >90%, but complete filling of the distal vessel. not through collateral vessels. within three cardiac cycles: 4 = subtotal occlusion. no distal filling within three cardiac cycles; and 5 = total occlusion with or without collateral distal filling. Patency of the infarct-related vessel was identified by grade 0. I. 3 or 3, whereas occlusion was indicated by grades 4 and 5 (2.1920).
Tllr hasc~linr sc\,rritq oj'c~oroncrp clrtery discrrsr HYIS tr1.w detrrrninrtl at the central laboratory by visual assessment of the percent reduction in luminal diameter of each coronary artery and its major branches. Left ventriculography was performed in the right anterior oblique projection; measurements of left ventricular e.jection fraction were obtained by the area-length method. Angiographic data were not obtained in eight patients in the rt-PA group and I I patients in the streptokinase group because of early death (n = I I), unwillingness to undergo the procedure (n = 6) or technically inadequate films (n = 2).
Echocardiography. Two-dimensional echocardiograph] was performed on the day of admission. after the administration of thrombolytic therapy and before hospital discharge. Each study consisted of parasternal long-and shortaxis views and apical two and four chamber views. In patients in whom these views were suboptimal, the subxiphoid window was utilized. For the purpose of analysis the left ventricle was divided into I I segments considering the apex as a single segment. Each myocardial segment was scored for wall motion using semiquantitative visual analysis score: normal motion 0. hypokinesia I, akinesia 2. dyskinesia 3 and aneurb'sm 4. Therefore, a left ventricular index score was constructed for each study. Left ventricular ejection fraction was calculated according to Simpson's rule. Each study was recorded on videotape and later scored independently in a central hbOrdtOry by two observers who were unaware of patient identity. therapy and effects of therapy. One hundred sixteen patients had a satisfactory examination both on admission and before discharge; 61 patients were treated with rt-PA and 55 with streptokinase.
Blood coagulation tests and evaluation of bleeding complications. Venipunctures were performed atraumatically with I9 gauge needles using a two syringe technique. Blood samples (9 vol) were collected on citrate (I vol) (final concentration 0.01 M) or on citrate containing aprotinin (Trasylol, Bayer) (final concentration 200 kIU/ml) before and 90 and I80 min after the beginning of thrombolysis. Blood was centrifuged within I h and plasma frozen immediately. Fibrintogen) level5 were measured by a clotting rate assal (2 I): other assays included fibrin and fibrinogen degradation products (22) . plasminogen (with use of chromogenic substrate S-22.51, Kabi Diagnostica) (23) and cu,-antiplasmin (24) . These measurements were made in two experienced coagulation laboratories. Activated partial thromboplastin time as well as the prothrombin time were measured conventionally by the hospital central hematology laboratory. The values of plasminogen, c+ antiplasmin and prothrombin time were expressed in percent by comparison with a standard curve obtained by serial dilutions of a normal plasma pool. Bleeding was characterized by site and qualified as "major" if there was a decrease in hemoglobin ~5 gi dl or any intracranial bleeding (8). Statistical analysis. All values are expressed as mean 2 I SD. Paired and unpaired t tests were used to compare the means of continuous variables. Data that did not follow the normal distribution were compared by an appropriate nonparametric test (Mann-Whitney U test). Chi-square tests (with Yates' correction when indicated) were used to compare discontinuous variables. A two-tailed method was used throughout and a 0.05 level of significance was used as a criterion to reject the null hypothesis.
Results
Patient data (Table 1 ). The two groups (rt-PA versus streptokinase) were similar in age, gender ratio. cardiovascular characteristics, site of infarction and interval between the onset of pain and the initiation of thrombolysis. The full treatment dose was administered to all 86 patients allocated to the rt-PA group. The infusion of streptokinase was stopped in 4 (4.7%) of the 85 patients because of severe (Table 2 ). The overall estimated reperfusion rate was high in both groups (87% in the rt-PA versus 80% in the streptokinase group, p = NS). On average the reperfusion time was 78 min in the rt-PA group and 81 min in the streptokinase group (p = NS). The recurrence of chest pain and ST segment elevation, however, was frequent after reperfusion; these signs of estimated reocclusion occurred in 20 patients in the rt-PA group (24%) and 8 patients in the streptokinase group (lo%, p = 0.015) with a delay, respectively, of 77 versus 48 min (p = NS). The reocclusion was transient in 14 patients in the rt-PA group (70%, mean duration of reocclusion 37 min) and in 7 patients in the streptokinase group (87%, mean duration of reocclusion 26 min) (p = NS). As a result, the ultimate reperfusion rate at 240 min after initiation of thrombolysis was 79% in both groups. Plasma MB CK activity peaked at 10.8 2 4.9 h in the rt-PA group and at 10.5 t 4.4 h in the streptokinase group (p = NS). Enzymatic infarct size was, respectively, 37.6 ? 24.6 *See text for definition. Abbreviations as in Table I. ejection fraction did not differ significantly between the two groups at the time of hospital admission. In the rt-PA group left ventricular ejection fraction improved from 52 + 11% to 56 + 10% before hospital discharge (p < 0.01). Similarly the left ventricular index score decreased from 0.42 ? 0.39 to 0.33 t 0.31 (p < 0.01). No significant improvement in ejection fraction was observed in the streptokinase group, whereas the left ventricular index score decreased from 0.47 * 0.37 to 0.40 t 0.37 (p < 0.05).
Clinical outcomes (Table 5 ). During the first 180 min from the beginning of thrombolysis, the prevalence of hypotension was almost doubled in the streptokinase group (22 versus 12%) but the difference was not statistically signifiand 32.0 2 20.6 g-Eq/m2 (p = NS). Angiographic data (Table 3 ). Cardiac catheterization was performed later in the hospital course 98 ? 41 h after rt-PA infusion and 95 2 47 h after streptokinase infusion (p = NS). There was a 7% difference between the groups in patency of the infarct-related vessel (81% in the rt-PA-treated group and 74% in the streptokinase-treated group, p = NS). More in the two groups. Echocardiographic data (Table 4 ). Echocardiographically determined left ventricular regional wall motion score and *Within 24 h after thrombolysis; tp < 0.01; jp < 0.05; $no significance. LVEF = left ventricular ejection fraction; LVIS = left ventricular index score. Other abbreviations as in Table I . Table I cant (p = 0.09). In addition four patients in the streptokinase group developed allergic reactions. Patients treated with rt-PA showed a more frequent occurrence of accelerated idioventricular rhythm (14% versus 6%: p = 0.07) and recurrence of chest pain, as outlined in the reperfusion section. During the subsequent hospital course clinical and ECG findings of recurrent myocardial ischemia occurred in IS patients (17%) assigned to rt-PA treatment and 13 patients (IS'%) assigned to streptokinase treatment. However. only two patients in the streptokinase group versus none in the rt-PA group developed a definite reinfarction (confirmed by recurrent MB CK elevation). lntrahospital mortality was lower in the rt-PA group (four versus seven patients: 4.6% versus 8.2% [p =: NS]). In the rt-PA group, the cause of death was cardiogenic shock in three patients and electromechanical dissociation in one patient. In the streptokinase group, death was due to cardiogenic shock in two patients and to pulmonary edema in two: one patient each died of electromechanical dissociation, reinfarction or intracranial bleeding.
Hemostatic variables and bleeding complications (Tables 6   and 7 ). During the infusion of rt-PA, fibrinogen levels decreased to 81% of the preinfusion levels at 90 min and to 63% after I80 min. In the streptokinase group fibrinogen levels decreased, respectively, to 21% and 16% (both p < 0.01). A decrease below 1 g/liter was observed in two patients in the rt-PA group at 90 min and in six patients at 180 min and. respectively. in 61 and 74 patients in the streptokinase group (both p < 0.0001). The fibrin(ogen) degradation products levels were much higher in the streptokinase group at 90 and at 180 min (both p < 0.01). The decrease in plasma plasminogen activity was less in rt-PA patients at 90 and at I80 min (both p < 0.01). However. alpha,-antiplasmin was almost exhausted in both groups, with no significant difference between the 78% reduction at 180 min in the rt-PA group compared with the 86% reduction in the streptokinase group. Global clotting assays were altered more consistently in the streptokinase group. During the first 180 min, when only thrombolytic agents were infused, one patient in each group developed bleeding at puncture sites. One additional rt-PA patient showed oozing from the gums. When heparin was added, bleeding complications cumulated to a total of 9% in the rt-PA group and 7% in the streptokinase group (p = NS). Bleeding complications were easily managed, with the exception of a fatal intracranial hemorrhage in one patient in the streptokinase group. The proportion of patients showing a decline in hemoglobin >3 g/dl was significantly higher in the streptokinase group (26% versus 14%; p = 0.05). No patient in the rt-PA group showed a decline 25 gidl, as opposed to five patients assigned to streptokinase treatment (p = 0.02).
Discussion
Coronary reperfusion with single chain rt-PA versus streptokinase. In this study a comparison was made between single chain rt-PA (2.5) at the recently recommended total intravenous dose of 100 mg (26) and intravenous streptokinase (1.5 million units over 60 min). Previous comparisons between rt-PA and streptokinase were performed using double chain rt-PA (1,2). The study was single blind and patients were randomized 43 h of the onset of symptoms. Reperfusion was detected noninvasively by frequent assessment of ST segment elevation, chest pain intensity and enzyme washout. This method has a sound physiologic basis and has been extensively validated from a clinical point of view (12-U). Data provide additional information about the thrombolytic process that is not immediately available when analyzing coronary patency at a single predetermined time after infusion of the thrombolytic agent. Reperfusion time varied widely among individuals and signs of reocclusion after reperfusion were frequently observed. The rate of reperfusion was significantly higher in the rt-PA group than in the streptokinase group during the first 30 min, but subsequent reocclusions were more frequent with rt-PA. As a result, the proportion of patients showing sustained reperfusion was similar in both groups (79% at 240 min after the beginning of thrombolysis). These high reperfusion rates might be explained by the short duration of symptoms before treatment, and support the in vitro observations of an increased resistance of thrombi to lysis as they age, because of continuing polymerization and cross-linking of the fibrin (27) .
Coronary patency. Coronary angiography was performed on average 4 days after hospital admission in both groups. The infarct-related vessel was found patent in 81% of patients in the rt-PA group and in 74% of patients assigned to streptokinase treatment. These data, consistent with a previous observation (20), suggest that the recurrence of ischemic episodes during and immediately after thrombolysis with rt-PA may be transient and that the risk of late stable coronary reocclusion with this agent is not higher than the risk with streptokinase. These results are also in agreement with the observation that no patients in the rt-PA group and only two in the streptokinase group developed clinical signs of reinfarction during the hospital stay.
Hemostasis. The results of this study confirm that the fibrinolytic system is activated during the infusion of single chain rt-PA (28) . However, the hemostatic defect was less marked than that observed in the streptokinase group. The 52% decline in plasma plasminogen activity in the rt-PA group was significantly lower than that in the streptokinase group (82%). Although the activity of the naturally occurring inhibitor alpha,-antiplasmin was almost exhausted in both groups, plasma levels of fibrin(ogen) degradation products were much higher in the streptokinase group. Fibrinogen levels decreased to <I g/liter in only 6 (7%) patients in the rt-PA group as opposed to 74 patients (87%) treated with streptokinase.
Bleeding complications. Bleeding complications are still to be expected in patients treated with rt-PA, particularly when cardiac catheterization is performed before and during thrombolysis (1.7,s). In this study early cardiac catheterization was avoided and, accordingly, bleeding rates were lower than those in previous studies. Although significant bleeding events were rare with both thrombolytic agents. one patient in the streptokinase group developed a fatal intracranial hemorrhage; on the whole, decreases in hemoglobin were significantly more frequent and larger after streptokinase infusion. Because all hemorrhagic complications took place after full heparinization had been undertaken, it is difficult to attribute their frequency to thrombolytic agents alone. Heparin, in addition to its anticoagulant action, causes several lipolytic enzymes to be released into the circulation and leads to raised levels of plasma free fatty acid concentration (29) , which may exert deleterious effects during reperfusion (30). Hence, the role of intravenous heparin in the setting of thrombolytic therapy must be elucidated.
Conclusions. Single chain rt-PA, at the recently recommended intravenous cumulative dose of 100 mg, yields high coronary reperfusion rates (79%). The patency of the infarctvessel at follow-up angiography (81%) along with the absence of reinfarction during the hospital stay confirm that the risk of sustained reocclusion is low. In comparison with intravenous streptokinase the hemostatic system was significantly spared. The infusion of rt-PA was not associated with intracranial bleeding and allergic reactions. Further advantages over streptokinase, in terms of mortality and morbidity, are to be tested by larger scale clinical trials.
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